Document is current
Any future updates will be listed below
-
Authors
Domizi, Pablo https://orcid.org/0000-0003-2903-0337
Sarno, Jolanda https://orcid.org/0000-0003-3488-0248
Jager, Astraea
Merchant, Milton
Pacheco, Kaithlen Zen B.
Yamada-Hunter, Sean A. https://orcid.org/0000-0002-4372-6587
Rotiroti, Maria Caterina
Liu, Yuxuan
Baskar, Reema https://orcid.org/0000-0002-3872-0164
Reynolds, Warren D.
Sworder, Brian J.
Sahaf, Bita
Bendall, Sean C. https://orcid.org/0000-0003-1341-2453
Mullighan, Charles G. https://orcid.org/0000-0002-1871-1850
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
Leahy, Allison B.
Myers, Regina M.
Yates, Bonnie
Wang, Hao-Wei https://orcid.org/0000-0002-5408-9253
Shah, Nirali N. https://orcid.org/0000-0002-8474-9080
Majzner, Robbie G. https://orcid.org/0000-0001-6969-8011
Mackall, Crystal L. https://orcid.org/0000-0001-6323-4304
Grupp, Stephan A. https://orcid.org/0000-0001-8030-7595
Barrett, David M.
Sotillo, Elena https://orcid.org/0000-0002-3993-1932
Davis, Kara L. https://orcid.org/0000-0002-7182-2592
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA251858)
V Foundation for Cancer Research (Pediatric Immunotherapy Grant)
- License Information
-
More Information
Article History
Received: 16 February 2025
Accepted: 2 April 2025
First Online: 23 April 2025
Competing interests
: N.N.S. receives research funding from Lentigen, VOR Bio, and CARGO Therapeutics. N.N.S. has attended advisory board meetings (no honoraria) for VOR, ImmunoACT, and Sobi. S.A.G.: Research and/or clinical trial support: Novartis, Servier, Cellectis, Vertex, and Kite. Study steering committees, consulting, and/or scientific advisory boards: Novartis, Allogene, Adaptive, Cabaletta, CRISPR/Vertex, Jazz, Estrella, Eureka, Bioline Rx, and Verismo. Toxicity management patents are managed by U Penn policies. K.L.D. Research support: Jazz Pharmaceuticals, BD Biosciences, and Kite-Gilead Pharmaceuticals. Advisory Board with honoraria: Novartis. The remaining authors declare no competing interests.
